News

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief of hematology at Children’s Hospital of Philadelphia discussed dual approval of the 2 gene therapies that coincided with ASH’s 2023 conference.

Ocugen and the FDA have agreed on trial design aspects including end point, patient enrollment strategy, and study duration.

CGTLive spoke with Donald Wood, PhD, president and CEO of the MDA while looking ahead to its March conference.

The associate professor at Peter MacCallum Cancer Centre discussed further research and questions that need to be investigated with the cell therapy.

ONCT-808 targets ROR1 and is currently being evaluated for the treatment of r/r aggressive B-cell lymphoma.

ACGT is advancing cell and gene therapy research for pancreatic tumors and other types of cancer.

These, among many others, are some of the key clinical trials of gene, cell, and regenerative therapies that the CGTLive staff will be following throughout 2024.

Take a look at the stories that stood out as pillars of progress and success in endocrinology gene and cell therapy development in 2023.

Take a look back at the 2023 conference, hosted by the University of Calgary and McMaster University, and held in Banff, Alberta, Canada.

Take a look at our most-read features from 2023 that explored the biggest current topics and concerns with gene and cell therapy development across treatment fields.

Take a look at the stories that stood out as pillars of progress and success from all of CGTLive's coverage of major 2023 medical society meetings and conferences.

Take a look at the interviews that stood out as pillars of progress and success from all of CGTLive's coverage of major 2023 medical society meetings and conferences.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Take a look at the stories that stood out as pillars of progress and success in cardiology gene and cell therapy development in 2023.

Take a look at the stories that stood out as pillars of progress and success in ophthalmology cell therapy development in 2023.

Take a look at the stories that stood out as pillars of progress and success in lysosomal storage disease gene and cell therapy development in 2023.

Take a look at the stories that stood out as pillars of progress and success in neurology gene and cell therapy development in 2023.

Take a look at the stories that stood out as pillars of progress and success in dermatology gene and cell therapy development in 2023.

Take a look at the stories that stood out as pillars of progress and success in endocrinology gene and cell therapy development in 2023.

Take a look at the stories that stood out as pillars of progress and success in oncology cell therapy development in 2023.

Take a look at the stories that stood out as pillars of progress and success in hematology gene and cell therapy development in 2023.

Review top news and interview highlights from the week ending December 22, 2023.

uniQure plans to initiate regulatory discussions in the US and Europe in the first quarter of 2024.

The company characterized the meeting as “productive”.

The associate professor at Fred Hutch Cancer Center discussed new data on the CD20-targeting CAR he presented at ASH 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Throughout 2023, interest in the application of CAR-T and other cell therapies to B-cell-driven autoimmune disease skyrocketed, with a multitude of clinical trials being initiated by various companies.